on our to supporting Thank everyone. I'll our as updates you, updates pipeline. work as generate Today, Linda, few well providing NASH on PBC, in our on and development Ocaliva evidence a good be and morning, program continued
Looking PBC. first at
meeting someone and of sources make on and disease, substantial data prevent to are therapy clinical on evidence PBC, Ocaliva mentioned to measures. end-stage when from beyond generating these living the we liver year chemical the to focused present Ocaliva trial the completing setting last clinical that to progression real-world decision-making the both the The we PBC the transplant-free of from databases individuals trial a publish quarter, As COBALT positive eligible, of which survival not benefit death, their show To that open-label statistically community. we which the generate POISE transplantation study end, did analysis with leveraging the were help III and Ocaliva. we later clinical liver for longer we extension, receive they PBC is Phase multiple data, clinical very regarding on ultimate on to to continue feedback positive therapy and goal These long-term expect events that those this to are year, impact benefit IV were physicians PBC, from to external different last in who but Ocaliva with on individuals Phase receiving data from difference for has sets liver compared pilot in outcomes. at showed pleased
data year. submissions will included these EMA our support Importantly, to of in study, half the this be regulatory COBALT, second and both FDA and as post-marketing for
communicated, COBALT previously available we've associated therapy. a of retaining especially commercially multiyear a with we've our placebo-controlled there's As closed in patients because study, when challenges study,
a the We including expanded events liver indicate the than new hospitalization COBALT, death. primary toward decompensation. are clinical compiling earlier that clinical includes for endpoint a liver demonstrating benefit final events, has transplant primary progression of from endpoint and higher primary that for sensitivity endpoint data The available placebo-controlled original Ocaliva's new
weeks line data and when top on in analysis We coming look forward completing them available. to the are sharing working
prespecified compilation of patients data COBALT our from Ocaliva data randomized patients a who with will received comparison sets. include Additionally, from external
outcomes we study, real-world For with leverage COBALT called our Phase the from later the behind these trial closure intend include initiated Ocaliva's to the our collectively this important Heroes, evidence we've of retrospective Cobalt, III impact extension outcomes. reasons and supportive open-label in Along studies on POISE regulatory which real-world as to evidence two submissions clinical data assess data same from year.
We're of Phase study to new III sharing look analyses results. from Now, the on our data REGENERATE excited and to completion nearing these be NASH. forward
the assessment will analyses the around submission, patient safety new include of X,XXX who've As X the more therefore meeting and the and OCA's years of than safety intend A we a in REGENERATE. NASH. scheduled with provide in X,XXX of on June, a potential currently on these years will the reached discussion is to the continue database much data X,XXX nearly compared pre-submission to more comprehensive now insight in profile for submission. benefit-risk reminder, The structure content patients FDA and prior robust
we X,XXX potential has expressed of data XXX FDA different or including histology include population in analysis resubmission. The populations Although recently our primary NASH, of non-invasive population final interest analysis in of NIT, on the over the tests will interest for original details mirror totality a additional for plan, received which subjects interim on our the will with data feedback subjects.
the consider entire new which includes will analyses XXX population, the subjects. Additional histology
can any patient with review, population any As FDA within evaluate the agency submission. a
toward III We Phase continuing from top a line compensated quarter. line data top study NASH. late-stage only study, anticipate active REVERSE from We the are to data delivering work REVERSE to third also our due in readout cirrhosis the in
Phase clinical We unprecedented. will the the analyses, we these REVERSE the assess results these III in ultimately, dialogue we in role have once set are agency data will completion we is with ongoing field. of amount REGENERATE data and in our accumulated of largest NASH data have trial of Overall, generating in upon with the hand. And the the
on Moving our to pipeline.
add screen fixed-dose PBC. our combination continue patients and sites our II U.S.-based OCA We bezafibrate for Phase in of clinical to study
continue dosing In evaluating OCA-beza of international II the addition, our is Phase combination. we enroll that to study regimens different
Phase in selection study large these will better Our dose design X the our the study the trial. the ongoing. and I potential for exposure drug-drug of remains Phase and III studies interactions data combination Together, characterize fixed-dose any to inform U.S.
our Finally, about in additional to I plans open for We call our study forward this turn next-generation track on indication and the agonist, intended now IND INT-XXX financial comprehensive over the Andrew sharing information a look weeks. we for to year. update. development Phase are for coming is have will Andrew? to INT-XXX, ongoing, an later our and I FXR
